Pharmafile.com’s weekly COVID-19 news round-up
pharmafile | June 10, 2020 | News story | Research and Development | COVID-19, coronavirus, round up, top 10
Hydroxychloroquine as a potential coronavirus treatment continues to be a contentious issue, as a new study led by researchers at the University of Minnesota finds it does not protect people from COVID-19, while The Lancet’s editors have expressed their concerns over a paper published in their journal that said hydroxychloroquine and chloroquine was dangerous for use in COVID-19 patients.
In other news, the Trump administration has selected the finalists for the COVID-19 vaccine it is seeking to make widely available by the end of the year, while Kings College London has launched a clinical trial to investigate how effective a formulation of ibuoprofen is in reducing respiratory failure in coronavirus patients.
1. Kings College London launches trial investigating the effectiveness of ibuprofen in COVID-19 patients – Published 03/06/20
Kings College London has launched a clinical trial to investigate how effective a formulation of ibuoprofen is in reducing respiratory failure in coronavirus patients.
2. Trump’s Operation Warp Speed selects Pfizer, Merck, AstraZeneca and Moderna as vaccine finalists – Published 04/06/20
The Trump administration has selected the finalists for the COVID-19 vaccine it is seeking to make widely available by the end of the year.
3. Lancet expresses concern over published hydroxychloroquine and chloroquine paper – Published 03/06/20
The Lancet’s editors have expressed their concerns over a paper published in their journal that said hydroxychloroquine and chloroquine was dangerous for use in COVID-19 patients.
4. Hydroxychloroquine does not work as a preventative against COVID-19, new study finds – Published 04/06/20
The malaria drug hydroxychloroquine does not protect people from COVID-19, according to a new study led by researchers at the University of Minnesota.
5. Australian Taskforce recommends Gilead’s remdesivir for routine use in the country’s COVID-19 patients – Published 05/06/20
Australia could be set to follow the decisions of other nations around the world in officially licensing Gilead’s antiviral therapy remdesivir in the treatment of COVID-19, after the country’s National COVID-19 Clinical Evidence Taskforce, a specialist team bringing together some of Australia’s leading health groups, has given its recommendation for routine use of the drug.
Related Content
COVID-19 vaccine eligibility creates challenges for UK pharmacies
Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …
Mental health medicine use in England reaches record high, NHSBSA report reveals
According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions …
FDA approves Moderna’s Spikevax for children at increased risk of COVID-19
Moderna has been granted US Food and Drug Administration (FDA) approval for its COVID-19 vaccine, …
